MedTrace Logo

Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer

NCT00895323 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as radionuclide imaging using bispecific antibody, may help find colorectal cancer cells and learn the extent of disease.

PURPOSE: This phase I trial is studying how well a bispecific antibody works in finding tumor cells in patients with colorectal cancer.

Conditions

Interventions

OTHER

enzyme-linked immunosorbent assay

OTHER

pharmacological study

PROCEDURE

whole-body scintigraphy

RADIATION

iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2

Sponsors & Collaborators

  • Garden State Cancer Center at the Center for Molecular Medicine and Immunology

    lead OTHER

Principal Investigators

  • Aiwu R. He, MD · Lombardi Comprehensive Cancer Center

Study Design

Purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00895323 on ClinicalTrials.gov